A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment.

Jennifer C DaviesEmil CarlssonAngela MidgleyEve M D SmithIan N BruceMichael W BeresfordChristian M Hedrichnull null

Published in: Rheumatology (Oxford, England) (2021)

Findings support the use of a urinary protein panel to identify active LN and potentially predict response to treatment with rituximab in adult SLE patients. Prospective studies are required to confirm findings.

Keyphrases

diffuse large b cell lymphoma
ejection fraction
end stage renal disease
newly diagnosed
rheumatoid arthritis
small molecule
combination therapy
young adults
binding protein
case control
replacement therapy